Regulatory | ApexOnco - Clinical Trials news and analysis

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

3 December 2024

FDA red and green lights: November 2024

Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.

Regulatory

28 November 2024

Kelun hits dato-dxd while it's down

Regulatory

27 November 2024

EU backs Tevimbra's stomach restriction – and then some

Regulatory

27 November 2024

Cabometyx’s Cabinet committee

Regulatory

22 November 2024

Targeted lung cancer niche sees a German pharma battle

But could toxicity be holding back filing plans?

Regulatory

19 November 2024

Jefferies 2024 – Arvinas gets a degrader delay

Regulatory

19 November 2024

Jefferies 2024 – Nuvation lays out its US taletrectinib strategy

Regulatory

18 November 2024

Syndax gets an early menin nod

Regulatory

14 November 2024

Not so fast for Astra in bladder cancer

Regulatory

12 November 2024

Astra shifts its dato lung focus again

Subscribe to Regulatory

FDA red and green lights: November 2024

Kelun hits dato-dxd while it's down

EU backs Tevimbra's stomach restriction – and then some

Cabometyx’s Cabinet committee

Targeted lung cancer niche sees a German pharma battle

Jefferies 2024 – Arvinas gets a degrader delay

Jefferies 2024 – Nuvation lays out its US taletrectinib strategy

Syndax gets an early menin nod

Not so fast for Astra in bladder cancer

Astra shifts its dato lung focus again

Recent Quick take

Most Popular